Diagnosis

Pityriasis rosea

An acute self-limiting papulosquamous disorder causing scaling rash mainly on the trunk and extremities lasting 2-10 weeks.

Also known as: Herpes tonsurans maculosus, Pityriasis circinata, Roseola annulata

Etiology

Cause [rtb]

  1. Unknown

  2. Infection (human herpes virus 6/7, influenza, diphtheria, smallpox, hepatitis B, pneumococcus, and COVID-19, bacteria, and spirochetes) is suspected due to:

    • Prodrome phase: Sore throat, gastrointestinal disturbance, fever, and arthralgia

    • Seasonal variation

    • Community clustering

    • Low rate of recurrence, which suggests immunity

  3. Noninfective causes like atopy, autoimmunity, vaccination, drugs (gold compounds, captopril, barbiturates, D-penicillamine, clonidine, ACE inhibitors, NSAIDs, hydrochlorothiazide, atypical antipsychotics, imatinib, metronidazole, isotretinoin, and clozapine)

Pathophysiology [rtb]

  1. Not entirely understood

  2. Trigger --> T-cell–mediated immune response --> characteristic skin pattern: [2s6]

    • A herald ("mother") patch surrounded by scaly oval plaques on the trunk and proximal extremities forming a characteristic "Christmas tree" appearance

Complications [rtb]

Epidemiology

Prevalence per 100.000 [g6n][zbd][rtb][4so][bsq][woz][pws][tzm][8sn][ktu]

Epidemiology chart for Prevalence

Incidence per 100.000 [g6n][zbd][rtb][4so][bsq][woz][pws][tzm][8sn][ktu]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

None listed.

Clinical findings

None listed.

Anamneses

None listed.

Localized findings

Rash
Radiates
CollumThoraxAbdomenArmBackLower body
Distribution
AsymmetricMultipleSingleSymmetric
Lesion type
ErythemaMaculePapulePlaqueVesicleUrticariaScaleLichenification
Lesion configuration
Target lesion
Lesion surface
Desquamation
Color
Red
Associated symptom
Itch

Approach

Diagnostic criteria [eir][yp7]

  1. Essential clinical features:

    • Discrete circular or oval lesions

    • Scaling on most lesions, and

    • Peripheral collarette scaling with central clearance on at least two lesions

  2. Optional clinical features:

    • Truncal and proximal limb distribution

    • Orientation of most lesions along skin cleavage lines

    • A herald patch (not necessarily the largest) appearing at least two days before eruption of other lesions

  3. Exclusional clinical features:

    • Multiple small vesicles at the centre of two or more lesions

    • Two or more lesions on palmar or plantar skin surfaces

    • Clinical or serological evidence of secondary syphilis

Treatment

  1. Self-limiting disease

  2. Supportive therapy: [rtb][eir]

    • Moisturizers

    • Bathing with soap alternatives

    • Cautious sunlight exposure without burning

    • Emollients

    • Antihistamines

  3. Therapy

    • Topical steroids

    • Acyclovir (considered in severe cases)

    • Macrolides (no proven benefit)

    • Narrowband ultraviolet B therapy

Differential diagnoses

Drug eruptions, Eczema, Erythema multiforme, Kaposi sarcoma, Lichen planus, Parapsoriasis, Pityriasis alba, Pityriasis versicolor, Psoriasis, Seborrheic dermatitis, Syphilis, Tinea corporis, Tinea versicolor


References

[1] Litchman G, Nair PA, Syed HA, et al. Pityriasis Rosea. Updated 2024 Mar 1: https://www.ncbi.nlm.nih.gov/books/NBK448091/

[2] Leung AKC, Lam JM, Leong KF, Hon KL. Pityriasis Rosea: An Updated Review. Curr Pediatr Rev. 2021;17(3):201-211.

[3] Chuh AA, Dofitas BL, Comisel GG, Reveiz L, Sharma V, Garner SE, Chu F. Interventions for pityriasis rosea. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005068.

[4] Chuang TY, Ilstrup DM, Perry HO, Kurland LT. Pityriasis rosea in Rochester, Minnesota, 1969 to 1978. J Am Acad Dermatol. 1982 Jul;7(1):80-9.

[5] Tay YK, Goh CL. One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singap. 1999 Nov;28(6):829-31.

[6] Ayanlowo O, Akinkugbe A, Olumide Y. The pityriasis rosea calendar: a 7 year review of seasonal variation, age and sex distributi

[7] Harman M, Aytekin S, Akdeniz S, Inalöz HS. An epidemiological study of pityriasis rosea in the Eastern Anatolia. Eur J Epidemiol. 1998 Jul;14(5):495-7.

[8] Cheong WK, Wong KS. An epidemiological study of pityriasis rosea in Middle Road Hospital. Singapore Med J. 1989 Feb;30(1):60-2.

[9] Ganguly S. A clinicoepidemiological study of pityriasis rosea in South India. Skinmed. 2013 May-Jun;11(3):141-6.

[10] Abercrombie GF. Pityriasis rosea 1964-65. J R Coll Gen Pract. 1968 Oct;16(4):268-74.

[11] Joshi TP, Calderara GA, Lipoff JB. Prevalence of pityriasis rosea in the United States: A cross-sectional study using the All of Us database. JAAD Int. 2022 May 19;8:45-46.

[12] Eisman S, Sinclair R. Pityriasis rosea. BMJ. 2015 Oct 29;351:h5233.

[13] Chuh AA. Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol. 2003 Jan;17(1):101-3.

[14] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]

Scroll to top